Landers et al. found CLDN4 was upregulated in both primary and metastatic tumor specimens compared with benign prostatic hyperplasia at both RNA and protein levels, and CLDN4 may be useful as a potential marker and therapeutic target for prostate metastases [21]. This evidence concerns the gene CLDN4 and metastatic neoplasm.